Ftse Mib
34.160,97
1,25%
DAX
19.984,32
0,74%
S&P 500
5.970,84
-1,11%
NASDAQ
19.722,03
-1,49%
Bitcoin
94.867,18
0,75%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrati per grafici in tempo reale, strumenti di analisi e prezzi.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Evaxion Biotech AS (EVAX) Evaxion Biotech AS (EVAX) Notizie

Evaxion Biotech AS

EVAX
1,08
0,234 (27,66%)
28 Dic 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Ricevuta di Deposito
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
26/12/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/12/202423:09EDGAR2Form F-1/A - Registration statement for certain foreign..
17/12/202414:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/12/202414:00GLOBEEvaxion pursues agreement with EIB to bolster equity through..
12/12/202414:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/12/202414:00GLOBEEvaxion establishes new AI-derived precision cancer vaccine..
09/12/202415:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/12/202414:00GLOBEEvaxion announces 2025 milestones reflecting continued..
05/12/202422:53EDGAR2Form F-1/A - Registration statement for certain foreign..
03/12/202412:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
02/12/202414:00GLOBEEvaxion to present preclinical Proof-of-Concept for..
18/11/202422:30EDGAR2Form F-1 - Registration statement for certain foreign..
13/11/202415:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/11/202414:00GLOBEEvaxion receives and appeals delisting determination from..
13/11/202413:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
13/11/202413:04EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/11/202414:00GLOBEEvaxion announces positive preclinical data for..
31/10/202415:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
31/10/202413:00GLOBEEvaxion announces business update and third quarter 2024..
28/10/202414:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/10/202413:00GLOBEEvaxion to announce business update and third quarter 2024..
09/10/202417:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/10/202414:00GLOBEStrong validation of Evaxion’s AI-Immunology™ platform in..
04/10/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/10/202414:00GLOBERecent clinical data confirms significantly improved..
03/10/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
01/10/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/9/202414:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/9/202413:30GLOBEEvaxion significantly expands vaccine development..
20/9/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/9/202414:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/9/202414:00GLOBEEvaxion launches improved AI-Immunology™ platform for..
16/9/202413:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
16/9/202413:00GLOBEEvaxion reports convincing one-year data from phase 2 trial..
09/9/202414:24EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/9/202414:22EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/9/202414:00GLOBEEvaxion reports 69% Overall Response Rate in its phase 2..
09/9/202413:00GLOBEEvaxion obtains pre-clinical Proof-of-Concept for mRNA..
23/8/202414:30EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
23/8/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
20/8/202414:45EDGAR2Form F-1/A - Registration statement for certain foreign..
19/8/202423:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202413:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202413:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/8/202413:00GLOBEEvaxion Announces Business Update and Second Quarter 2024..
12/8/202413:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/8/202413:27GLOBEEvaxion to Announce Business Update and Second Quarter 2024..
08/8/202414:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/8/202414:00GLOBEEvaxion to Present One-Year Clinical Efficacy Data from its..
02/8/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
Apertura: 1,0598 Min: 0,89 Max: 1,12
Chiusura: 0,846

La tua Cronologia

NASDAQ
EVAX
Evaxion Biotech AS
BIT
NSCIT0535590
Cipriani Profilati
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network